Rood Laboratory
About the Lab
-
Lab Focus Areas
Quantitative Proteomics Proteogenomic Discovery of Tumor-Specific Peptides as T cell Immunotherapy Targets
Tumor-Specific Peptides as Cerebrospinal Fluid Biomarkers Methylation-Based Liquid Biopsy Microsatellite-Based Cancer Predisposition -
Contact
Brian R. Rood, M.D. Medical Director, Brain Tumor Institute [email protected]
Featured Publications
-
Integrated proteogenomic characterization across major histological types of pediatric brain cancer
Francesca Petralia, Nicole Tignor, Boris Reva, Mateusz Koptyra, Shrabanti Chowdhury, Dmitry Rykunov, Azra Krek, Weiping Ma, Yuankun Zhu… *Adam C. Resnick,*Phillip B. Storm,*Brian R. Rood and *Pei Wang *co-corresponding authors Cell 23;183(7):1962-1985.e31 PMID: 33242424 December (2020) -
Germline microsatellite genotypes differentiate children with medulloblastoma
Rivero-Hinojosa S, Kinney N, Garner HR, Rood BR Neuro-Oncology 22(1):152-162 (2019) -
Proteomic analysis of medulloblastoma reveals functional biology with translational potential
Rivero-Hinojosa S, Lau LS, Stampar M, Staal J, Zhang H, Gordish-Dressman H, Northcott PA, Pfister SM, Taylor MD, Brown KJ, Rood BR Acta Neuropathol Commun 6(1):48. DOI: 10.1186/s40478-018-0548-7 PMID: 29880060 June (2018) -
Proteomic profiling of high risk medulloblastoma reveals functional biology
Staal, J., Lau, L., Zhang, H., Ingram, W., Hallahan, A., Northcott, P., Pfister, S., Wechsler-Reya, R., Rusert, J., Taylor, M., Cho, Y., Packer, R., Brown, K., Rood, BR. Oncotarget 10;6(16):14584-95. PMID: 25970789; PMCID: PMC4546489 June (2015) -
Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics
Rood BR, Leprince D Expert Opinion on Therapeutic Targets PMCID:PMC3683369 April (2013)